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Abstract 
 
Alteplase has been the mainstay of thrombolytic treatment since the National Institutes of 
Neurological Disorders and Stroke (NINDS) trial was published in 1995. Over recent years 
several trials have investigated alternative thrombolytic agents. Tenecteplase, a genetically 
engineered mutant tissue plasminogen activator, has a longer half-life, allowing single 
intravenous bolus administration without infusion, is more fibrin specific, produces less 
systemic depletion of circulating fibrinogen, and is more resistant to plasminogen activator 
inhibitor compared to alteplase. Tenecteplase is established as the first-line intravenous 
thrombolytic drug for myocardial infarction, where it has been shown to achieve comparable  
reperfusion with reduced risk of systemic bleeding in comparison to alteplase. We review 
the literature on tenecteplase for the treatment of acute ischemic stroke, with a focus on the 
major completed and ongoing trials. Overall tenecteplase shows promise for treatment of 
acute ischemic stroke, both in populations currently eligible for alteplase and also in groups 
not currently treated with thrombolysis. 
 
 
 
 
 
  
Standard thrombolytic treatment with alteplase 
Reperfusion is strongly associated with better outcome after stroke.1 Recent randomised 
controlled trials (RCTs) of endovascular thrombectomy, predominantly used as an adjunct to 
intravenous (IV) thrombolysis, emphasise the benefit of rapid and more complete reperfusion2-
4. Optimising intravenous thrombolytic therapy offers significant health gains, however, even 
in the era of endovascular treatment. While endovascular treatment offers an optimal standard 
of care for patients with anterior circulation large artery occlusion, intravenous thrombolytic 
treatment remains the first-line treatment for the majority of patients even in advanced health 
care systems, where only around 40% of patients eligible for IV thrombolysis meet current 
guideline criteria for endovascular treatment, and many more have restricted or delayed access 
to interventional centres.5, 6 Globally, access to endovascular treatment will be limited or absent 
in most countries in the immediate future, therefore intravenous thrombolytic treatment 
represents the only option for reperfusion therapy. Further, the benefits of endovascular 
treatment in recent randomised controlled trials were based on early initiation of thrombolytic 
drug therapy in the great majority of participants, and there is some evidence of synergistic 
effects.  
 
Thrombolytic treatment with the recombinant tissue plasminogen activator (rtPA) alteplase 
significantly increases the probability of excellent recovery (approximately 10% absolute and 
60% relative increase in the likelihood of recovery without significant neurological deficit in 
the most recent meta-analyses).6 While there are clear benefits from IV alteplase,6-8 clinical 
anxiety about risks – particularly of symptomatic intracerebral haemorrhage (SICH) – and 
variation in guidelines  lead many patients to not be treated9, 10 despite evidence of potential 
benefit from treatment and of  poor outcome when not treated11  A safer agent would 
potentially change the perceived risk to benefit ratio substantially, and allow a greater 
proportion of eligible patients to be treated. In stroke, alteplase achieves early recanalisation in 
fewer than 50% of patients,12 and, only half of those who recanalise do so within 2 hours of 
drug administration.13 Alteplase recanalises large artery occlusion (terminal internal carotid 
artery or proximal middle cerebral artery) within 2 hours in fewer than 10% of cases.12, 14 There 
is potentially substantial benefit from better IV thrombolytic agents. 
 
Tenecteplase – A promising thrombolytic drug for treatment of stroke 
Despite recognition of the limited efficacy of alteplase and availability of thrombolytic agents 
with potentially superior efficacy, better safety profile, and easier administration schedule, 
alteplase has remained the sole intravenous thrombolytic agent  for stroke since the NINDS trial 
in 1995.15 Clinical trials of desmoteplase, a thrombolytic drug with far greater fibrin specificity 
than alteplase, focused on late time windows among patients with imaging features thought to 
signify persistent viable penumbra.16-18 These studies failed to demonstrate efficacy, but with 
hindsight had issues with inconsistent application of imaging selection criteria, and failed to 
reach their target sample sizes. Tenecteplase, a genetically engineered mutant tPA, was 
developed to improve recanalisation19 over alteplase through higher affinity binding to fibrin, 
greater resistance to inactivation by Plasminogen Activator Inhibitor-1(PAI-1), less disruption 
of hemostasis, and longer free plasma half-life, allowing single IV bolus administration. This has 
substantial practical advantages over the 1 hour infusion of alteplase20, particularly as many 
patients are transferred between and within hospitals for treatments such as endovascular 
thrombectomy.21, 22 Tenecteplase is established as the first-line intravenous thrombolytic drug 
for myocardial infarction,23, 24 where it has been shown to achieve comparable reperfusion with 
reduced systemic haemorrhage in comparison to alteplase.25, 26  In stroke, data from small 
phase 2 trials suggest that these pharmacodynamic differences may result in higher 
recanalization rates without increased hemorrhage rates.27-29  
 
Completed trials of tenecteplase for acute ischemic stroke 
Prior to 2017, six small clinical studies of tenecteplase in acute stroke had been reported27, 30-32 
including three small RCTs.30 28 27 In two initial dose-finding safety studies, Haley and colleagues 
undertook an ascending dose safety RCT that evaluated tenecteplase doses between 0.1mg/kg 
and 0.5mg/kg,30 and a single centre Australian case series described use of the 0.1mg/kg dose 
in an extended treatment time window of 3-6 hours based on multimodal CT imaging 
selection.31  
In a subsequent RCT, Haley and colleagues discontinued recruitment to a higher dose group 
(0.4mg/kg) after only 19 subjects on the basis of early safety and efficacy data, but were unable 
to discriminate between 0.1mg/kg and 0.25mg/kg on grounds of either safety or efficacy.32 The 
Australian TNK trial28 reported superiority of tenecteplase 0.1mg/kg and 0.25mg/kg over 
alteplase in 75 patients, in terms of both imaging-defined reperfusion and clinical outcomes, in 
a selected group of patients with large artery occlusion and favourable brain perfusion patterns 
defined on computed tomography perfusion (CTP) up to 6 hours after stroke onset. The 
0.1mg/kg dose exhibited inferior recanalization and reperfusion compared to 0.25mg/kg, 
although both were superior to alteplase. The ATTEST single centre RCT compared alteplase 
with tenecteplase 0.25mg/kg and gathered imaging data for outcome evaluation and to 
characterise pathophysiology at baseline, but did not select on imaging criteria.27 Despite 
baseline imbalance with more negative prognostic features in the tenecteplase group (a higher 
proportion of large artery occlusion - 75% vs 61% - and 33% larger ischaemic core volume – 
representing irreversibly damaged tissue), there were trends towards greater earlier major 
neurological improvement and lower total ICH incidence in the tenecteplase-treated group. In 
a sub-study, tenecteplase was associated with significantly less disruption of the fibrinolytic 
system:22 alteplase caused significant reduction in fibrinogen, prolongation of prothrombin 
time, increase in PAI-1 activity and reduction of plasminogen over 24 hours, all of which are 
associated  with an increased risk of bleeding. Tenecteplase did not cause change in any of these 
parameters. Markers of clot lysis efficacy were, however, the same for both agents.  
In all of these prior studies, the target population was those eligible for intravenous 
thrombolysis, or a sub-group of eligible subjects defined by imaging. TEMPO-1 was  a phase 2 
dose-escalation safety study of tenecteplase in an extended time window  in a group,  with 
minor stroke, who are largely excluded from current guidelines.33 Fifty patients with minor 
stroke (NIHSS 0-5) and intracranial occlusion identified on CTA were treated with tenecteplase 
in a 12-hour window at 0.1 mg/kg (first tier of 25 patients) and 0.25 mg/kg (second tier of 25 
patients). Recanalization rates were higher with 0.25 mg/kg dosing (61%) and complete 
recanalization predicted excellent functional outcome (mRS 0-1) at 90 days (RR 1.65: 95%CI 
1.1-2.5, p=0.026). 
 
In an individual patient data meta-analysis of the three RCTs comparing tenecteplase and 
alteplase,30 28 27 the tenecteplase 0.25mg/kg dose (total n=216) was associated with a shift in 
distribution of modified Rankin Scale at 90 days in favour of tenecteplase (adjusted OR 1.4, 95% 
CI 0.5, 4.3) as well as showing a trend towards lower symptomatic intracranial hemorrhage 
rates (4/108 tenecteplase, 3.7% versus 7/108 alteplase, 6.5%, adjusted OR 0.7, 95% CI 0.2, 
2.5).34  
 
Since 2017, two multicentre RCTs have reported findings, NORTEST and EXTEND-IA TNK. 
The NORTEST study compared tenecteplase 0.4mg/kg to alteplase in adults with ischaemic 
stroke eligible for IV thrombolysis within 4.5 hours of onset, using only CT for imaging 
selection.35 The trial was much larger than previous studies (n=1100) and reported no 
difference between treatment arms with respect to either safety or efficacy. Interpretation of 
NORTEST is complicated by the predominance of very mild stroke patients (median NIHSS 
at baseline 4), high proportions of TIAs (7%) and stroke mimics (17%), and a high rate of 
protocol deviations (12%). EXTEND-IA TNK36 compared 0.25mg/kg tenecteplase versus 
0.9mg/kg alteplase in ischemic stroke patients with large vessel occlusion planned for 
thrombectomy. The primary outcome was substantial reperfusion of >50% of the involved 
territory by the time of the initial angiogram (which occurred at median 55min after 
thrombolysis was commenced). This technical efficacy endpoint was chosen as the 
thrombectomy procedure was felt to be likely to obscure any potential clinical benefit of 
tenecteplase. The trial aimed to establish non-inferiority of tenecteplase given that the cost 
and convenience advantages of tenecteplase would justify a change in practice provided it 
was convincingly similar in efficacy. In the final analysis tenecteplase achieved superior 
reperfusion at initial angiogram (in 22% vs 10% in the alteplase group, p=0.023, figure 1). 
The ordinal analysis of modified Rankin scale at 90 days also favoured tenecteplase (cOR 1.7, 
95%CI 1.0-2.8, p=0.037, figure 2). The difference between tenecteplase and alteplase was 
largely observed in patients with MCA occlusion and very few patients with ICA occlusion 
recanalized prior to angiography in either group. Key features of the completed tenecteplase 
studies are included in Table 1. 
 
Benefits of using imaging for selection of patients 
The trials of tenecteplase have used various approaches to imaging selection. Haley et al32 
and NORTEST used non-contrast CT only. ATTEST acquired CT perfusion but did not use it 
for selection into the trial. TEMPO-133 and EXTEND-IA TNK36  required vessel occlusion. 
TASTE28 required dual target vessel occlusion and CT perfusion mismatch.  
 
These differences in selection may explain some of the variation in results. While there was 
no clear benefit of tenecteplase in the overall ATTEST study, exploratory pooled individual 
patient data meta-analysis of the TASTE and ATTEST studies found that, while there was 
no significant overall interaction of imaging features with thrombolytic treatment group, 
patients with independently assessed vessel occlusion had improved recanalization (71% 
vs 43%, p<0.0001, figure 1), which translated into improved clinical outcomes (mRS 0-1 OR 
4.82, 95% CI 1.02–7.84, p=0.05, figure 2) with tenecteplase versus alteplase.37 Similarly the 
group with target mismatch on CT Perfusion had improved outcomes with tenecteplase 
versus alteplase (mRS 0-1 53% vs 24%, OR 2.33, 95% CI 1.13–5.94; P=0.032).38 An 
additional finding in the target mismatch group treated with tenecteplase was reduced 
parenchymal hematoma compared to alteplase-treated mismatch patients. 
 
These findings are consistent with pooled analyses of desmoteplase trials. Overall 
desmoteplase did not show benefit over placebo for thrombolysis beyond 3 hours. 
However, in post-hoc analyses the subgroup with vessel occlusion showed an increase in 
recanalization and improved outcomes with desmoteplase.39 Similarly, patients with a 
large mismatch using perfusion-diffusion MRI showed treatment benefit with 
desmoteplase.40 While there was no significant interaction of angiographic variables with 
treatment effect of alteplase given within 6 hours of stroke onset in the angiographic 
substudy of IST-3, the point estimates for treatment effect in patients without vessel 
occlusion were notably discordant with the estimates for treatment in those with 
occlusion: combining IST-3 with other alteplase and desmoteplase trials, there was a 
significant interaction between the presence of arterial occlusion and treatment effect 
(p=0.017).41 
 
In studies using tenecteplase, alteplase or desmoteplase, functional outcome among 
patients without vessel occlusion or mismatch was generally very good in both active and 
comparator groups, which  dilutes the overall treatment effect observed and thus requires 
larger sample sizes.42 The benefits of selection by vessel occlusion and/or mismatch can be 
illustrated by contrasting NORTEST and TEMPO-1, both of which a enrolled less severely 
affected patients but only TEMPO-1required vessel occlusion, and showed improved 
outcomes when tenecteplase achieved reperfusion.33 Large datasets of alteplase-treated 
patients with multimodal CT before treatment also suggest lack of demonstrable benefit 
when there is a small perfusion lesion (<15 mL) without occlusion when compared with 
similar untreated controls. 43    
 The ongoing trials TEMPO-2 (NCT02398656) and EXTEND-IA TNK II (NCT03340493) have 
continued to require vessel occlusion and TASTE (ACTRN12613000243718) requires CTP 
mismatch. The ATTEST-2 (NCT02814409) and TWIST (NCT03181360) trials do not require 
vessel occlusion, but both are collecting data on vessel occlusion status in subgroups. Key 
features of these ongoing RCTs are shown in Table 2. 
 
ONGOING TRIALS of TENECTEPLASE 
 Tenecteplase versus alteplase in disabling stroke: ATTEST-2 
The evidence base to date supports the hypotheses of potential improvements in both safety 
and efficacy of tenecteplase over alteplase, but does not provide conclusive evidence for 
either superiority or non-inferiority. That there are likely to be larger treatment effect sizes 
among those with imaging-defined therapeutic targets such as large vessel occlusion or 
substantial volumes of salvageable tissue is expected.42 Nonetheless, there are potentially 
important gains if efficacy could be established in a general thrombolysis-eligible population 
(under 4.5 hours, disabling deficit, standard guideline based inclusion/ exclusion criteria). 
based solely on universally available, simple imaging. Such a study requires a larger sample 
size than trials that select populations with imaging targets. The ongoing ATTEST-2 study 
therefore aims to recruit 1870 subjects based on CT and clinical criteria alone and compares 
tenecteplase 0.25mg/kg with alteplase 0.9mg/kg. Results are expected in around 2 years.  
 
Tenecteplase versus alteplase in patients with penumbra: TASTE trial 
The TASTE trial is enrolling acute stroke patients who are clinically eligible for intravenous 
thrombolysis, but who also fulfil target mismatch criteria on perfusion CT and using 
automated software to calculate lesion volumes (ischemic core <70 mL, penumbral >15 mL, 
mismatch ratio >1.8). The primary outcome is non-inferiority of tenecteplase to alteplase for 
proportions of patients with mRS 0-1 at 90 days. The calculated sample size is 400 patients, 
with an interim at 300 patients which will allow for sample size recalculation.  
  
Testing different doses of tenecteplase before thrombectomy for large vessel 
occlusion: The EXTEND-IA TNK II trial 
EXTEND-IA TNK II (NCT03340493) is now underway comparing the 0.25mg/kg dose 
versus 0.40mg/kg in patients with large vessel occlusion (ICA, MCA or basilar artery) who 
are planned for endovascular thrombectomy. The inclusion criteria are broad with no age, 
clinical severity or ischaemic core restrictions and inclusion of patients with a degree of 
pre-stroke disability (mRS 3). The primary outcome is substantial reperfusion (>50% of 
the involved territory i.e. mTICI 2b/3) or no retrievable thrombus at the initial 
angiographic assessment. Given the greater clot burden, large vessel occlusion patients 
may have the most to gain from a higher dose of tenecteplase.  
 
Tenecteplase versus non thrombolytic control for wake-up stroke: TWIST 
About one in five strokes occur during sleep44, but patients who have new stroke 
symptoms when they wake up from sleep (“wake-up stroke”) are currently excluded from 
thrombolytic treatment, because the time of stroke onset is unknown. Several studies have 
shown that the onset of stroke during sleep is close to awakening45, and that patients with 
wake-up stroke share many clinical and radiological findings with patients with stroke 
duration less than 4.5 hours.46, 47 The bolus administration and the very rapid onset of 
action makes tenecteplase a particularly attractive option for patients with wake-up stroke. 
The Tenecteplase in Wake-up Ischaemic Stroke Trial (TWIST) therefore aims to randomise 
500 patients with wake-up stroke to tenecteplase 0.25 mg/kg versus non-thrombolytic 
standard of care (NCT03181360). Inclusion is not based on imaging criteria, but CT 
Angiography is performed before inclusion and CT Perfusion is performed as part of a sub-
study.   
 
Tenecteplase versus non thrombolytic control for minor stroke with intracranial 
artery occlusion: TEMPO-2 trial 
In minor stroke, where the balance between safety and efficacy is even more critical, 
tenecteplase may be a pharmacologically superior agent. The TEMPO-2 trial is randomizing 
1,274 minor stroke patients with intracranial occlusion to tenecteplase 0.25mg/kg versus 
non-thrombolytic standard of care (NCT02398656). To be included patients need to be 
assessed as non-disabling based on their presenting deficits (NIHSS 0-5). Patients need to 
treated within 12 hours of onset and within 90 minutes of the CT/CTA. Patients will be 
included if they have a premorbid mRS of 0-2. Primary outcome is a responder analysis at 90 
days with 0-1 being a good outcome in patients with a pre-morbid mRS of 0,1 and 2 being a 
good outcome in patients with a pre-morbid mRS of 2. 
 
Conclusions 
Tenecteplase shows promise for the treatment of all types of acute ischemic stroke. From a 
practical point of view tenecteplase is easier to use as it is quickly administered as a single 
bolus. Emerging data suggest that tenecteplase has higher recanalization rates and is at least 
as safe as alteplase. Trials are ongoing that are comparing tenecteplase with alteplase, and 
testing tenecteplase in subgroups of patients with ischemic stroke. Thrombolytic treatment 
will continue to be a key part of the treatment of acute stroke worldwide and using a better 
thrombolytic such as tenecteplase will have a global impact. 
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Trial Year Study 
design 
TNK Dose 
Groups 
(mg/kg) 
Non-TNK 
thrombolytic 
Comparator Group 
N 
Haley30 2005 RCT 0.1vs 0.2 vs 
0.4 vs 0.5 
No 88 
Parsons31 2009 Obs 0.1 No 15 
Haley48 2010 Obs 0.1 vs 0.25 vs 
0.4 
Alteplase 0.9mg/kg 112 
Parsons28 2012 RCT 0.1 vs 0.25 Alteplase 0.9mg/kg 75 
ATTEST27 2015 RCT 0.25 Alteplase 0.9mg/kg 104 
TEMPO-133 2015 Obs 0.1 vs 0.25 No 50 
NOR-TEST35 2017 RCT 0.4 Alteplase 0.9mg/kg 1100 
EXTEND-IA 
TNK36 
2018 RCT 0.25 Alteplase 0.9mg/kg 202 
Kate49 2018 Obs 0.25 No 16 
RCT Randomized-controlled trial; Obs Observational study 
Table 1: Completed trials of tenecteplase for acute ischemic stroke  
 
 
 
 
Trial TNK Dose 
Groups 
(mg/kg) 
Non-TNK 
thrombolytic 
Comparator Group 
Timing N 
ATTEST-2 
(NCT02814409) 
0.25 Alteplase 0.9mg/Kg <4.5 hours 1870 
TASTE-2  
(ACTRN12613000243718) 
0.25 Alteplase 0.9mg/Kg <4.5 hours Up to 
1024* 
EXTEND-IA TNK II  
(NCT03340493) 
0.25 vs 0.4 No  Up to 
656* 
TWIST (NCT03181360) 0.25 No (Non-
thrombolytic 
standard of care) 
<4.5 hours 
from 
awakening 
500 
TEMPO-2 
(NCT02398656) 
0.25 No (Non-
thrombolytic 
standard of care) 
<12 hours 1274 
 
Table 2: Ongoing randomized-controlled trials of tenecteplase for acute ischemic 
stroke. * adaptive sample size 
 
 
 
 
 
 
 
Figure 1: Recanalization with tenecteplase versus alteplase in patients with baseline 
vessel occlusion at approximately 1 hour post-treatment (22% vs 10% p=0.023, 
EXTEND-IA TNK36) and at 24 hours post-treatment (71% vs 43%, p<0.001, pooled 
analysis37 of  ATTEST and Australian TNK trial). 
 
 
 
 Figure 2: Distribution of modified Rankin scale scores at 90 days in patients with 
baseline vessel occlusion treated with a) thrombolysis and thrombectomy in EXTEND-
IA TNK (cOR 1.7 95%CI 1.0-2.8, p=0.037)36 and b) thrombolysis only (cOR 3.2, 95% CI 
1.4-8.3, p=0.009) in pooled analysis of ATTEST and Australian TNK trial.37 
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